Drug Type Small molecule drug |
Synonyms Xaliproden, Xaliproden hydrochloride (JAN), xaliprodene + [6] |
Target |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC24H23ClF3N |
InChIKeyWVHBEIJGAINUBW-UHFFFAOYSA-N |
CAS Registry90494-79-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01537 | Xaliproden Hydrochloride |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | NDA/BLA | EU | - | |
Colonic Cancer | Phase 3 | US | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | CA | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | FR | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | DE | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | GR | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | IT | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | ES | 01 Jan 2008 | |
Colonic Cancer | Phase 3 | GB | 01 Jan 2008 | |
Sensory neuropathy | Phase 3 | US | 01 Jan 2008 |
Phase 3 | Metastatic Colorectal Carcinoma First line | 649 | Placebo | jtsicwkbef(psnrcnycvb): hazard ratio = 0.61 (95% CI, 0.4 - 0.93), P-Value = 0.0203 View more | Positive | 20 Jun 2006 | |